Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension
Identifieur interne : 001487 ( Istex/Corpus ); précédent : 001486; suivant : 001488Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension
Auteurs : J. M. Senard ; P. Valet ; G. Durrieu ; M. Berlan ; M. A. Tran ; J. L. Montastruc ; A. Rascol ; P. MontastrucSource :
- European Journal of Clinical Investigation [ 0014-2972 ] ; 1990-12.
English descriptors
- KwdEn :
Abstract
Abstract. The adrenergic status was studied through evaluation of platelet α2‐adrenoceptor number ([3H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P < 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml‐1, (P < 0.05) when compared with controls (219 pM 13 pg ml‐1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml‐1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P < 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg‐1) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg‐1) or with controls (0.68 pM 0.l μg kg‐1). Platelet x2‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg‐1 protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg‐1 protein) or in controls (175 pM 4 fmol mg‐1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α2‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.
Url:
DOI: 10.1111/j.1365-2362.1990.tb01909.x
Links to Exploration step
ISTEX:BC9DFB38359C3E0570C44CC5E126E572C41AB6D0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Valet, P" sort="Valet, P" uniqKey="Valet P" first="P." last="Valet">P. Valet</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, P" sort="Montastruc, P" uniqKey="Montastruc P" first="P." last="Montastruc">P. Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BC9DFB38359C3E0570C44CC5E126E572C41AB6D0</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1111/j.1365-2362.1990.tb01909.x</idno><idno type="url">https://api.istex.fr/document/BC9DFB38359C3E0570C44CC5E126E572C41AB6D0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001487</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001487</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Valet, P" sort="Valet, P" uniqKey="Valet P" first="P." last="Valet">P. Valet</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, P" sort="Montastruc, P" uniqKey="Montastruc P" first="P." last="Montastruc">P. Montastruc</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Clinical Investigation</title><idno type="ISSN">0014-2972</idno><idno type="eISSN">1365-2362</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1990-12">1990-12</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="613">613</biblScope><biblScope unit="page" to="619">619</biblScope></imprint><idno type="ISSN">0014-2972</idno></series><idno type="istex">BC9DFB38359C3E0570C44CC5E126E572C41AB6D0</idno><idno type="DOI">10.1111/j.1365-2362.1990.tb01909.x</idno><idno type="ArticleID">ECI613</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2972</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>orthostatic hypotension</term><term>plasma catecholamines</term><term>platelet</term><term>α2‐adrenoceptors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Abstract. The adrenergic status was studied through evaluation of platelet α2‐adrenoceptor number ([3H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P < 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml‐1, (P < 0.05) when compared with controls (219 pM 13 pg ml‐1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml‐1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P < 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg‐1) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg‐1) or with controls (0.68 pM 0.l μg kg‐1). Platelet x2‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg‐1 protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg‐1 protein) or in controls (175 pM 4 fmol mg‐1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α2‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>J. M. SENARD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item><json:item><name>P. VALET</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item><json:item><name>G. DURRIEU</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item><json:item><name>M. BERLAN</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item><json:item><name>M. A. TRAN</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item><json:item><name>J. L. MONTASTRUC</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</json:string></affiliations></json:item><json:item><name>A. RASCOL</name><affiliations><json:string>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</json:string></affiliations></json:item><json:item><name>P. MONTASTRUC</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>α2‐adrenoceptors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>orthostatic hypotension</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>plasma catecholamines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>platelet</value></json:item></subject><articleId><json:string>ECI613</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Abstract. The adrenergic status was studied through evaluation of platelet α2‐adrenoceptor number ([3H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P > 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml‐1, (P > 0.05) when compared with controls (219 pM 13 pg ml‐1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml‐1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P > 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg‐1) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg‐1) or with controls (0.68 pM 0.l μg kg‐1). Platelet x2‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg‐1 protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg‐1 protein) or in controls (175 pM 4 fmol mg‐1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α2‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.</abstract><qualityIndicators><score>6.957</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1759</abstractCharCount><pdfWordCount>3957</pdfWordCount><pdfCharCount>24706</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>261</abstractWordCount></qualityIndicators><title>Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title><refBibs><json:item><author><json:item><name>JG MacLeod</name></json:item><json:item><name>RR. Tuck</name></json:item></author><host><volume>21</volume><pages><last>30</last><first>419</first></pages><author></author><title>Ann Neurol</title></host><title>Disorders of the autonomic nervous system: part 1. pathophysiology and clinical features</title></json:item><json:item><author><json:item><name>M. Gross</name></json:item><json:item><name>R. Bannister</name></json:item><json:item><name>R. Godwin‐Austen</name></json:item></author><host><volume>i</volume><pages><last>6</last><first>174</first></pages><author></author><title>Lancet</title></host><title>Orthostatic hypotension in Parkinson's disease</title></json:item><json:item><author><json:item><name>L. Orskov</name></json:item><json:item><name>J. Jakobsen</name></json:item><json:item><name>E. Dupont</name></json:item><json:item><name>B. de Fine Olivarius</name></json:item><json:item><name>NJ. Christensen</name></json:item></author><host><volume>37</volume><pages><last>8</last><first>1173</first></pages><author></author><title>Neurology</title></host><title>Autonomic function in parkinsonian patients relates to duration of disease</title></json:item><json:item><author><json:item><name>G. Micieli</name></json:item><json:item><name>E. Martignoli</name></json:item><json:item><name>A. Cavallini</name></json:item><json:item><name>G. Sandrini</name></json:item><json:item><name>G. Nappi</name></json:item></author><host><volume>37</volume><pages><last>93</last><first>386</first></pages><author></author><title>Neurology</title></host><title>Postprandial and orthostatic hypotension in Parkinson's disease</title></json:item><json:item><author><json:item><name>RJ Polinsky</name></json:item><json:item><name>IJ Kopin</name></json:item><json:item><name>MH Ebert</name></json:item><json:item><name>V. Weise</name></json:item></author><host><volume>31</volume><pages><last>7</last><first>1</first></pages><author></author><title>Neurology</title></host><title>Pharmacologic distinction of different orthostatic hypotension syndroms</title></json:item><json:item><author><json:item><name>MS Kafka</name></json:item><json:item><name>RJ Polinsky</name></json:item><json:item><name>A. Williams</name></json:item></author><host><volume>34</volume><pages><last>5</last><first>1121</first></pages><author></author><title>Neurology</title></host><title>Alpha‐adrenergic receptors in orthostatic hypotension syndroms</title></json:item><json:item><author><json:item><name>V. Tredelenberg</name></json:item></author><host><volume>15</volume><pages><last>76</last><first>225</first></pages><author></author><title>Pharmacol Rev</title></host><title>Supersensitivity and subsensitivity to sympathomimetic amines</title></json:item><json:item><author><json:item><name>RJ Polinsky</name></json:item><json:item><name>DS Goldstein</name></json:item><json:item><name>RT Brown</name></json:item><json:item><name>HR Keiser</name></json:item><json:item><name>IJ. Kopin</name></json:item></author><host><volume>18</volume><pages><last>53</last><first>48</first></pages><author></author><title>Ann Neurol</title></host><title>Decreased sympathetic neuronal uptake in idiopathic orthostatic hypotension</title></json:item><json:item><author><json:item><name>P. Valet</name></json:item><json:item><name>C. Damase‐Michel</name></json:item><json:item><name>B. Chamontin</name></json:item><json:item><name>D. Durand</name></json:item><json:item><name>F. Chollet</name></json:item><json:item><name>JL. Montastruc</name></json:item></author><host><volume>18</volume><pages><last>5</last><first>481</first></pages><author></author><title>Eur J Clin Invest</title></host><title>Platelet alpha2‐and leukocyte beta2‐adrenoceptors in phaeochromocytoma: effect of tumor removal</title></json:item><json:item><author><json:item><name>A. Villeneuve</name></json:item><json:item><name>M. Berlan</name></json:item><json:item><name>M. Lafontan</name></json:item></author><host><volume>15</volume><pages><last>7</last><first>403</first></pages><author></author><title>Eur J Clin Invest</title></host><title>Platelet alpha2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment</title></json:item><json:item><author><json:item><name>MM. Bradford</name></json:item></author><host><volume>72</volume><pages><last>54</last><first>248</first></pages><author></author><title>Ann Biochem</title></host><title>A rapid and sensitive method for the quantitation of protein utilizing the principle of protein by binding</title></json:item><json:item><author><json:item><name>O. Rascol</name></json:item><json:item><name>JL Montastruc</name></json:item><json:item><name>JM Senard</name></json:item><json:item><name>JF Demonet</name></json:item><json:item><name>M. Simonetta</name></json:item><json:item><name>A. Rascol</name></json:item></author><host><volume>38</volume><pages><last>91</last><first>1387</first></pages><author></author><title>Neurology</title></host><title>Two weeks of treatment with deprenyl (selegiline) does not prolong L‐dopa effect in Parkinsonian patients: a double blind cross‐over placebo controlled trial</title></json:item><json:item><author><json:item><name>PE Cryer</name></json:item><json:item><name>S. Weiss</name></json:item></author><host><volume>33</volume><pages><last>7</last><first>275</first></pages><author></author><title>Arch Neurol</title></host><title>Reduced plasma noradrenaline response to standing in autonomic dysfunction</title></json:item><json:item><author><json:item><name>MG Ziegler</name></json:item><json:item><name>CR Lake</name></json:item><json:item><name>IJ. Kopin</name></json:item></author><host><volume>296</volume><pages><last>7</last><first>293</first></pages><author></author><title>N Engl J Med</title></host><title>The sympathetic nervous system defect in primary orthostatic hypotension</title></json:item><json:item><author><json:item><name>D. Robertson</name></json:item><json:item><name>MR Goldberg</name></json:item><json:item><name>CS Tung</name></json:item><json:item><name>AS Hollister</name></json:item><json:item><name>RM. Robertson</name></json:item></author><host><volume>78</volume><pages><last>81</last><first>576</first></pages><author></author><title>J Clin Invest</title></host><title>Use of alpha2‐adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system</title></json:item><json:item><author><json:item><name>CN Corder</name></json:item><json:item><name>TM Kanefsky</name></json:item><json:item><name>RH MacDonald</name></json:item><json:item><name>JL Gray</name></json:item><json:item><name>DP. Redmond</name></json:item></author><host><volume>27</volume><pages><last>7</last><first>921</first></pages><author></author><title>Neurology</title></host><title>Postural hypotension: adrenergic responsitivity and levodopa therapy</title></json:item><json:item><author><json:item><name>M. Berlan</name></json:item><json:item><name>O. Rascol</name></json:item><json:item><name>J. Belin</name></json:item><json:item><name>JP Moatti</name></json:item><json:item><name>A. Rascol</name></json:item><json:item><name>JL. Montastruc</name></json:item></author><host><volume>12</volume><pages><last>44</last><first>138</first></pages><author></author><title>Clin Neuropharmacol</title></host><title>Alpha2‐adrcnergic sensitivity in Parkinson's disease</title></json:item><json:item><author><json:item><name>J. Onrot</name></json:item><json:item><name>MR Goldberg</name></json:item><json:item><name>I. Biaggioni</name></json:item><json:item><name>RG Wiley</name></json:item><json:item><name>AS Hollister</name></json:item><json:item><name>D. Robertson</name></json:item></author><host><volume>37</volume><pages><last>20</last><first>215</first></pages><author></author><title>Neurology</title></host><title>Oral yohimbine in human autonomic failure</title></json:item><json:item><author><json:item><name>LC Mahan</name></json:item><json:item><name>RM MacKernan</name></json:item><json:item><name>PA. Insel</name></json:item></author><host><volume>27</volume><pages><last>35</last><first>215</first></pages><author></author><title>Ann Rev Pharmacol Toxicol</title></host><title>Metabolism of alpha‐and beta‐adrenergic receptors in vitro and in vivo</title></json:item><json:item><author><json:item><name>OE Brodde</name></json:item><json:item><name>KD. Bock</name></json:item></author><host><volume>26</volume><pages><last>7</last><first>265</first></pages><author></author><title>Eur J Clin Invest</title></host><title>Changes in platelet alpha 2 adrenoceptors in human phaeochromocytoma</title></json:item><json:item><author><json:item><name>CR Jones</name></json:item><json:item><name>HL Elliot</name></json:item><json:item><name>N. Deighton</name></json:item><json:item><name>CA Howie</name></json:item><json:item><name>JL. Reid</name></json:item></author><host><volume>3</volume><pages><last>155</last><first>153</first></pages><author></author><title>J Hypert</title></host><title>Alpha adrenoceptor number and function in platelets from treated and untreated patients with essential hypertension and age and sex matched controls</title></json:item><json:item><author><json:item><name>K. Sakagushi</name></json:item><json:item><name>R. Hattori</name></json:item><json:item><name>Y. Yui</name></json:item></author><host><volume>55</volume><pages><last>8</last><first>434</first></pages><author></author><title>Br Heart J</title></host><title>Altered platelet alpha2‐adrenoreceptor in acute myocardial infarction and its relation to plasma catecholamine concentrations</title></json:item><json:item><author><json:item><name>H. Kaufmann</name></json:item><json:item><name>T. Brannan</name></json:item><json:item><name>L. Krakoff</name></json:item><json:item><name>MD Yahr</name></json:item><json:item><name>J. Mandelli</name></json:item></author><host><volume>38</volume><pages><last>6</last><first>951</first></pages><author></author><title>Neurology</title></host><title>Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha‐adrenergic agonist (midodrine)</title></json:item><json:item><author><json:item><name>NH Hoehn</name></json:item><json:item><name>MD. Yahr</name></json:item></author><host><volume>17</volume><pages><last>42</last><first>427</first></pages><author></author><title>Neurology</title></host><title>Parkinsonism: onset, progression and mortality</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>20</volume><publisherId><json:string>ECI</json:string></publisherId><pages><total>7</total><last>619</last><first>613</first></pages><issn><json:string>0014-2972</json:string></issn><issue>6</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1365-2362</json:string></eissn><title>European Journal of Clinical Investigation</title><doi><json:string>10.1111/(ISSN)1365-2362</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>medicine, research & experimental</json:string><json:string>medicine, general & internal</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>general clinical medicine</json:string></scienceMetrix></categories><publicationDate>1990</publicationDate><copyrightDate>1990</copyrightDate><doi><json:string>10.1111/j.1365-2362.1990.tb01909.x</json:string></doi><id>BC9DFB38359C3E0570C44CC5E126E572C41AB6D0</id><score>0.0932561</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/BC9DFB38359C3E0570C44CC5E126E572C41AB6D0/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/BC9DFB38359C3E0570C44CC5E126E572C41AB6D0/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BC9DFB38359C3E0570C44CC5E126E572C41AB6D0/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1990</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title><author xml:id="author-1"><persName><forename type="first">J. M.</forename><surname>SENARD</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author><author xml:id="author-2"><persName><forename type="first">P.</forename><surname>VALET</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author><author xml:id="author-3"><persName><forename type="first">G.</forename><surname>DURRIEU</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author><author xml:id="author-4"><persName><forename type="first">M.</forename><surname>BERLAN</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author><author xml:id="author-5"><persName><forename type="first">M. A.</forename><surname>TRAN</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author><author xml:id="author-6"><persName><forename type="first">J. L.</forename><surname>MONTASTRUC</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</affiliation></author><author xml:id="author-7"><persName><forename type="first">A.</forename><surname>RASCOL</surname></persName><affiliation>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">P.</forename><surname>MONTASTRUC</surname></persName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation></author></analytic><monogr><title level="j">European Journal of Clinical Investigation</title><idno type="pISSN">0014-2972</idno><idno type="eISSN">1365-2362</idno><idno type="DOI">10.1111/(ISSN)1365-2362</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1990-12"></date><biblScope unit="volume">20</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="613">613</biblScope><biblScope unit="page" to="619">619</biblScope></imprint></monogr><idno type="istex">BC9DFB38359C3E0570C44CC5E126E572C41AB6D0</idno><idno type="DOI">10.1111/j.1365-2362.1990.tb01909.x</idno><idno type="ArticleID">ECI613</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1990</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Abstract. The adrenergic status was studied through evaluation of platelet α2‐adrenoceptor number ([3H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P < 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml‐1, (P < 0.05) when compared with controls (219 pM 13 pg ml‐1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml‐1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P < 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg‐1) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg‐1) or with controls (0.68 pM 0.l μg kg‐1). Platelet x2‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg‐1 protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg‐1 protein) or in controls (175 pM 4 fmol mg‐1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α2‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>α2‐adrenoceptors</term></item><item><term>orthostatic hypotension</term></item><item><term>Parkinson's disease</term></item><item><term>plasma catecholamines</term></item><item><term>platelet</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1990-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/BC9DFB38359C3E0570C44CC5E126E572C41AB6D0/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2362</doi><issn type="print">0014-2972</issn><issn type="electronic">1365-2362</issn><idGroup><id type="product" value="ECI"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF CLINICAL INVESTIGATION">European Journal of Clinical Investigation</title></titleGroup></publicationMeta><publicationMeta level="part" position="12006"><doi origin="wiley">10.1111/eci.1990.20.issue-6</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="1990-12">December 1990</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0061300" status="forIssue"><doi origin="wiley">10.1111/j.1365-2362.1990.tb01909.x</doi><idGroup><id type="unit" value="ECI613"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="tocHeading1">Original Article</title></titleGroup><eventGroup><event type="firstOnline" date="2008-06-28"></event><event type="publishedOnlineFinalForm" date="2008-06-28"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.15 mode:FullText" date="2010-07-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-20"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="613">613</numbering><numbering type="pageLast" number="619">619</numbering></numberingGroup><correspondenceTo>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ECI.ECI613.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 15 June 1989 and in revised form 19 April 1990</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="24"></count><count type="linksCrossRef" number="9"></count></countGroup><titleGroup><title type="main">Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>J. M.</givenNames><familyName>SENARD</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>P.</givenNames><familyName>VALET</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>G.</givenNames><familyName>DURRIEU</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>M.</givenNames><familyName>BERLAN</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>M. A.</givenNames><familyName>TRAN</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1" corresponding="yes"><personName><givenNames>J. L.</givenNames><familyName>MONTASTRUC</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a2"><personName><givenNames>A.</givenNames><familyName>RASCOL</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1"><personName><givenNames>P.</givenNames><familyName>MONTASTRUC</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FR"><unparsedAffiliation>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">α<sub>2</sub>‐adrenoceptors</keyword><keyword xml:id="k2">orthostatic hypotension</keyword><keyword xml:id="k3">Parkinson's disease</keyword><keyword xml:id="k4">plasma catecholamines</keyword><keyword xml:id="k5">platelet</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract. </b> The adrenergic status was studied through evaluation of platelet α<sub>2</sub>‐adrenoceptor number ([<sup>3</sup>H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (<i>P</i> < 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml<sup>‐1</sup>, (<i>P</i> < 0.05) when compared with controls (219 pM 13 pg ml<sup>‐1</sup>) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml<sup>‐1</sup>). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (<i>P</i> < 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg<sup>‐1</sup>) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg<sup>‐1</sup>) or with controls (0.68 pM 0.l μg kg<sup>‐1</sup>). Platelet <i>x</i><sub>2</sub>‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg<sup>‐1</sup> protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg<sup>‐1</sup> protein) or in controls (175 pM 4 fmol mg<sup>‐1</sup> protein) with no change in <i>K</i><sub>d</sub>. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α<sub>2</sub>‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension</title></titleInfo><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">SENARD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">VALET</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">DURRIEU</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">BERLAN</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. A.</namePart><namePart type="family">TRAN</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. L.</namePart><namePart type="family">MONTASTRUC</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Inserm U3I7. Faculte de Medicine, Centre Hospitalier Universitaire. 37 Allees Jules Guesde, 31073 Toulouse. CEDEX, France.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">RASCOL</namePart><affiliation>*Service de Neurologie, Centre Hospitalier Universitaire Purpan, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">MONTASTRUC</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medicine, Centre Hospitalier Universitaire, Toulouse</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1990-12</dateIssued><edition>Received 15 June 1989 and in revised form 19 April 1990</edition><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">24</extent></physicalDescription><abstract>Abstract. The adrenergic status was studied through evaluation of platelet α2‐adrenoceptor number ([3H]‐yohimbine binding sites), plasma catecholamine levels and blood pressure response to noradrenaline infusion in three groups of subjects (1) Parkinsonians with orthostatic hypotension; (2) Parkinsonians without orthostatic hypotension; and (3) control subjects. In Parkinsonians with orthostatic hypotension, systolic and diastolic blood pressures significantly (P < 0.05) decreased from 144 pM 9 and 76 pM 6 mmHg in the lying position to 95 pM 12 and 60 pM 7 mmHg after 5 min standing. In these patients, noradrenaline plasma levels were significantly low (62 pM 11 pg ml‐1, (P < 0.05) when compared with controls (219 pM 13 pg ml‐1) whereas no difference was noticed in Parkinsonians without orthostatic hypotension (195 pM 14 pg ml‐1). The noradrenaline dose required for a 25 mmHg increase in systolic blood pressure was significantly (P < 0.01) lower in Parkinsonians with orthostatic hypotension (019 pM 0.03 μg kg‐1) when compared with Parkinsonians without orthostatic hypotension (0.86 pM 0.11 μg kg‐1) or with controls (0.68 pM 0.l μg kg‐1). Platelet x2‐adrenoceptor number was higher in Parkinsonians with orthostatic hypotension (313 pM 52 fmol mg‐1 protein) than in Parkinsonians without orthostatic hypotension (168 pM 9 fmol mg‐1 protein) or in controls (175 pM 4 fmol mg‐1 protein) with no change in Kd. This study demonstrates that in patients with Parkinson's disease, orthostatic hypotension is associated with an increase in both vascular sensitivity to noradrenaline and platelet α2‐adrenoceptor number. These observations suggest the existence of an α‐adrenergic supersensitivity in response to the low levels of plasma noradrenaline.</abstract><subject lang="en"><genre>keywords</genre><topic>α2‐adrenoceptors</topic><topic>orthostatic hypotension</topic><topic>Parkinson's disease</topic><topic>plasma catecholamines</topic><topic>platelet</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Clinical Investigation</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0014-2972</identifier><identifier type="eISSN">1365-2362</identifier><identifier type="DOI">10.1111/(ISSN)1365-2362</identifier><identifier type="PublisherID">ECI</identifier><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>613</start><end>619</end><total>7</total></extent></part></relatedItem><identifier type="istex">BC9DFB38359C3E0570C44CC5E126E572C41AB6D0</identifier><identifier type="DOI">10.1111/j.1365-2362.1990.tb01909.x</identifier><identifier type="ArticleID">ECI613</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:BC9DFB38359C3E0570C44CC5E126E572C41AB6D0
|texte= Adrenergic supersensitivity in Parkinsonians with orthostatic hypotension
}}
| This area was generated with Dilib version V0.6.29. |  |